Cargando…

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations

PURPOSE: Treatment-resistant depression (TRD) is associated with profound morbidity for patients, placing a significant burden on those affected, the health service and wider society. Despite this, TRD remains chronically underserved in terms of viable treatment options. To address this gap, an advi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, Allan H, Abdelghani, Mohamed, Juruena, Mario F, Nikolova, Viktoriya L, Nilforooshan, Ramin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968662/ https://www.ncbi.nlm.nih.gov/pubmed/36861011 http://dx.doi.org/10.2147/NDT.S388392

Ejemplares similares

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
por: Bossaller, Nicholas A., et al.
Publicado: (2020)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder
por: Liberman, Joshua, et al.
Publicado: (2023)

WhatsApp Doc?
por: Gould, Georgina, et al.
Publicado: (2016)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis
por: Samalin, L., et al.
Publicado: (2023)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
por: Diekamp, Bettina, et al.
Publicado: (2021)

Effects of preoperative nasal spray esketamine on separation anxiety and emergence agitation in pediatric strabismus surgery: A randomized clinical trial
por: Liu, Wei, et al.
Publicado: (2022)

Comparative analysis of the dispersion quality of oxymetazoline nasal sprays
por: Gobyzov, Oleg A., et al.
Publicado: (2022)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray
por: Rozjabek, Heather, et al.
Publicado: (2022)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

High Energy Physics Advisory Panel
Publicado: (2007)

Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers
por: Mischel, Nicholas A., et al.
Publicado: (2021)

Liposomal Nasal Spray versus Guideline-Recommended Steroid Nasal Spray in Patients with Chronic Rhinosinusitis: A Comparison of Tolerability and Quality of Life
por: Eitenmüller, Anna, et al.
Publicado: (2014)

National advisory panels for paediatric cancer in the UK as an example of rare cancer multidisciplinary team meetings
por: Brown, S, et al.
Publicado: (2021)

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
por: Saad, Ziad, et al.
Publicado: (2020)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
por: Castro, Meredith, et al.
Publicado: (2023)

Status report from CLIC advisory panel
por: CERN. Geneva
Publicado: (1986)

The vision and scope of the prophylactic dressing standard initiative of the European Pressure Ulcer Advisory Panel and National Pressure Injury Advisory Panel
por: Brienza, David, et al.
Publicado: (2022)

Was WHO SARS-related Travel Advisory for Toronto Ethical?
por: Paquin, Leo J.
Publicado: (2007)

The ESCMID ethics advisory committee (EEAC): purpose and challenges
por: Righi, Elda, et al.
Publicado: (2022)

A critique of the WHO TobReg's "Advisory Note" report entitled: "Waterpipe tobacco smoking: health effects, research needs and recommended actions by regulators"
por: Chaouachi, Kamal
Publicado: (2006)

Intra-nasal Esketamine Induced Psychotic Disorder in a Post Covid-19 Major Depressive Episode: a case report
por: Tang, Julie, et al.
Publicado: (2023)

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
por: Ionescu, Dawn F, et al.
Publicado: (2020)

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
por: Oliveira-Maia, Albino J., et al.
Publicado: (2023)

Identification and Treatment of Patients with Homozygous Familial  Hypercholesterolaemia: Information and Recommendations from a  Middle East Advisory Panel
por: Al-Ashwal, Abdullah, et al.
Publicado: (2015)

Canada’s National Advisory Committee on Immunization: Celebrating 50 years
por: Desai, Shalini, et al.
Publicado: (2015)

Office of Science; High Energy Physics Advisory Panel
por: Samuel, R M
Publicado: (2003)

UTAP Meeting : SSC Underground Technology Advisory Panel
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_3leheb2sbvv6rc0kml937l5ks2